4Chamberlin W,Graham DY,Hulten K,et al.Review article:Mycobacterium avium subsp.paratuberculosis as one cause of Crohn's disease[J].Aliment Pharmacol Ther,2001,15(3):337-346 被引量：1
5Naser SA,Ghobrial G,Romero C,et al.Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease[J].Lancet.2004,364(9439):1039-1044 被引量：1
6Lavy A,Broide E,Reif S,et al.Measles is more prevalent in Crohn's disease patients.A multicentre Israeli study[J].Dig Liver Dis,2001,33(6):472-476 被引量：1
9Halme L,Turunen U,Paavola-Sakki P,et al.CARD15 frameshift mutation in patients with CROHN disease is associated with immune dysregulation[J].Scand J Gastroenterol,2004,39(12):1243 -1249 被引量：1
10Sugimura K,Taylor KD,Lin YC,et al.A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews[J].Am J Hum Genet,2003,72(3):509-518 被引量：1
二级参考文献43
1[1]Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine,1995; 7: 15～25. 被引量：1
2[2]Plevy SE, Landers C J, Prehn J, et al. A role for TNF-a and mucosal T helper-1 cytokines in the pathogenesis of Crohnis disease. J Immunol, 1997; 159: 6276～6282. 被引量：1
3[3]Garnett WR, Yunker N. Treatment of Crohnis disease with infliximab. Am J Health Syst Pharm, 2001; 58nn-: 307～316. 被引量：1
4[4]Targan SR, Hanauer SB, van Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohnis disease. N Engl J Med, 1997; 337:1029～1035. 被引量：1
5[5]Rutgeerts P, DiHaens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab)to maintain remission in Crohnis disease. Gastroenterology, 1999;117: 761～769. 被引量：1
6[6]Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohnis disease. N Engl J Med, 1999;340:1398～1405. 被引量：1
7[7]DiHaens G, van Deventer S, van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohnis disease: a European multicenter trial.Gastroenterology, 1999; 116: 1029～1034. 被引量：1
8[8]Baert FJ, DiHaens G, Peeters M, et al. Tumor necrosis factor a antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohnis ileocolitis. Gastroenterology, 1999;116: 22～28. 被引量：1
9[9]Schreiber S, Kuehbacher T, Mascheretti S, et al. Clinical efficacy of treatment with infliximab in a German multicenter, prospective,open-label trial in refractory Crohnis disease. Gastroenterology,2000; 118(Suppl.2): A568. 被引量：1
10[10]Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohnis disease in clinical practice at the Mayo Clinic: the first 100 patients.Gastroenterology, 2000; 118(Suppl.2): A568. 被引量：1
